1
|
Sarathi Chakraborty D, Choudhury S, Lahiry S. Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia. Sleep Sci 2023; 16:256-264. [PMID: 37425970 PMCID: PMC10325868 DOI: 10.1055/s-0043-1770805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/11/2023] Open
Abstract
Insomnia is one of the major challenges in medical science nowadays as it leads to great socio-economic burden by impairing daytime function as well as the development of exhaustion, depression, and memory disturbance in affected individuals. Several important classes of drugs have been tried, including the BZDs and non-BZD hypnotics. Available drugs to combat this disease have the limitations of abuse potential, tolerance, and cognitive impairment. In some instances, withdrawal symptoms have been observed upon the abrupt cessation of those drugs. The Orexin system has been very recently targeted as a therapeutic option to overcome those limitations. Treatment of insomnia with Daridorexant as a Dual Orexin Receptor Antagonist (DORA) has been evaluated in several preclinical and clinical studies. Available information obtained from those studies has shown a promising future for this drug in the management of insomnia. Beyond its effectiveness in insomnia, it has been successfully used in patients suffering from obstructive sleep apnoea, chronic obstructed airway disease (COAD), Alzheimer's disease (AD), hypertension, and cardiovascular disorders. Larger studies need to address the safety issues as well as obtain robust pharmacovigilance information to safeguard the risk-benefit aspect of this drug in insomniac adults.
Collapse
Affiliation(s)
| | | | - Sandeep Lahiry
- Independent Research Scholar, Barasat, Kolkata, West Bengal, India
| |
Collapse
|
2
|
Chatterjee S, Chakraborty DS, Choudhury S, Lahiry S. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Curr Drug Res Rev 2022; 14:20-23. [PMID: 34872487 DOI: 10.2174/2589977513666211206100749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 07/16/2021] [Accepted: 10/11/2021] [Indexed: 11/22/2022]
Abstract
The incidence of carbapenem-resistant gram-negative (CRGNB) bacterial infections has increased globally. The wide diversity of strains, multiplicity of infections, and rapid development and spread of resistance are a matter of great concern both in community and hospital settings. Cefiderocol is a novel injectable siderophore containing cephalosporin with potent microbicidal activity against most carbapenem-resistant Enterobacteriaceae (CRE). It has recently been approved by USFDA for the treatment of complicated urinary tract infections (cUTI) caused by susceptible gram-negative microorganisms. This review focuses on the salient pharmacological profile of the drug and the clinical studies that were undertaken. Cefiderocol is first in class injectable siderophore cephalosporin showing potency against carbapenem- resistant Enterobacteriaceae. It has recently been approved by US FDA for the treatment of adult patients with complicated urinary tract infections (cUTI) caused by susceptible Gram-negative microorganisms, where there are limited or no alternative treatment options.
Collapse
Affiliation(s)
- Suparna Chatterjee
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | - Dwaipayan Sarathi Chakraborty
- Department of Pharmacology, Diamond Harbour Government Medical College and Hospital, Diamond Harbour, West Bengal, India
| | - Shouvik Choudhury
- Department of Pharmacology, Burdwan Medical College and Hospital, Burdwan, West Bengal, India
| | - Sandeep Lahiry
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| |
Collapse
|
3
|
Choudhury S, Bala M, Chakraborty DS, Lahiry S. Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia. Lung India 2021; 38:300-301. [PMID: 33942766 PMCID: PMC8194436 DOI: 10.4103/lungindia.lungindia_93_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Shouvik Choudhury
- Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India
| | - Moumita Bala
- Department of Pharmacology, Midnapore Medical College, Midnapore, West Bengal, India
| | | | | |
Collapse
|
4
|
Abstract
OBJECTIVE In May 2020, the International Society of Hypertension (ISH) published "Practice Guidelines for the Management of Hypertension." The ISH 2020 guidelines were developed based on evidence criteria (i) to be used globally, (ii) to be fit for application in low-middle-income and high-income settings, and (iii) to be concise, simple, and easy to use by clinicians, nurses, and community health workers, as appropriate. The defined purpose was to adhere to the current evidence and develop a balanced proposal for global use in line with the ISH mission. METHODOLOGY Multiple novel approaches have been included keeping in mind about lifestyle modification and flexibility in treatment options. RESULTS AND CONCLUSIONS The ISH 2020 guidelines are practical and physician friendly. It also proves immensely helpful for low-resource countries without national guidelines on the management of hypertension.
Collapse
Affiliation(s)
- Dwaipayan Sarathi Chakraborty
- Department of Pharmacology, Diamond Harbour Government. Medical College, Diamond Harbour, India
- *Dwaipayan Sarathi Chakraborty,
| | | | | |
Collapse
|
5
|
Lahiry S, Thakur S, Chakraborty DS. New Drugs and Clinical Trials Rules-2019: What academicians need to know. Indian J Dermatol Venereol Leprol 2020; 86:445-448. [PMID: 32394898 DOI: 10.4103/ijdvl.ijdvl_790_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Sandeep Lahiry
- Independent Scholar, Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
| | - Sayanta Thakur
- Junior Resident (Pharmacology), Institute of Postgraduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
| | | |
Collapse
|
6
|
Thakur S, Chakraborty DS, Lahiry S, Choudhury S. Osimertinib as an emerging therapeutic modality in nonsmall cell lung cancer: Opportunities and challenges in Indian scenario. Lung India 2020; 37:77-78. [PMID: 31898629 PMCID: PMC6961090 DOI: 10.4103/lungindia.lungindia_291_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Sayanta Thakur
- Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | | | - Sandeep Lahiry
- Department of Pharmacology, RG Kar Medical College, Kolkata, West Bengal, India
| | - Shouvik Choudhury
- Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India
| |
Collapse
|
7
|
Chakraborty DS, Hazra A, Sil A, Pain S. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Family Med Prim Care 2019; 8:3173-3178. [PMID: 31742138 PMCID: PMC6857390 DOI: 10.4103/jfmpc.jfmpc_522_19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 08/22/2019] [Accepted: 08/29/2019] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND AIMS Irritable bowel syndrome (IBS) is a chronic relapsing disorder characterized by abdominal pain-discomfort and altered bowel habits. The IBS-diarrhoea predominant subtype (IBS-D) is defined as >25% of bowel movements representing type 6 or 7 of the Bristol Stool Form Scale. Management of IBS-D is mainly symptomatic, including lifestyle modification. Due to absence of standard treatment, multiple drugs are used. A controlled release (CR) form of mebeverine, recommended for spasmodic gastrointestinal disorders (including IBS) has recently been introduced in Indian market. We have conducted a placebo-controlled double blind randomized controlled trial [CTRI/2018/03/012897] to evaluate the effectiveness and safety of this product. METHODS 40 patients of IBS-D were recruited from medicine out-patient department (OPD) of a tertiary care hospital and randomized to two parallel groups. One received mebeverine 200 mg CR tablets twice daily for 8 weeks, while other received matching placebo. Outcome parameters were number of bowel movements per day over past 7 days (NoBM7d), severity of abdominal cramps and IBS quality of life (IBSQoL) score. Medication adherence record and treatment emergent adverse events were captured. RESULTS Mebeverine group showed modest but statistically significant improvement in NoBM7d, cramps and IBSQoL from baseline to 4 and 8 weeks. The changes within the placebo group were not statistically significant. Also, the intergroup differences at both 4 and 8 weeks were not statistically significant. Adherence was better in mebeverine group and both interventions were well tolerated. CONCLUSIONS Mebeverine 200 mg CR twice daily has modest effect in IBS-D and therefore will not be a good choice for patients with severe symptoms.
Collapse
Affiliation(s)
| | - Avijit Hazra
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | - Amrita Sil
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | - Shantasil Pain
- Department of Medicine, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| |
Collapse
|
8
|
Mukherjee D, Lahiry S, Thakur S, Chakraborty DS. Effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis. J Family Med Prim Care 2019; 8:517-522. [PMID: 30984665 PMCID: PMC6436291 DOI: 10.4103/jfmpc.jfmpc_446_18] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: To assess effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis (RA). Materials and Methods: An open-labeled randomized trial was conducted comparing 60,000 IU 1,25 dihydroxy vitamin D3 + calcium (1000 mg/day) combination [Group A] versus calcium (1000 mg/day) only [Group B], as supplement to existing treatment regimen in early RA. Primary outcome included (i) minimum time required for onset of pain relief (Tm) assessed through patients’ visual analog scale (VAS); (ii) % change in VAS score from onset of pain relief to end of 8 weeks. Secondary outcome included change in disease activity score (DAS-28). Results: At the end of 8-weeks, Group A reported 50% higher median pain relief scores (80% vs. 30%; P < 0.001) and DAS-28 scores (2.9 ± 0.6 vs. 3.1 ± 0.4; P = 0.012) compared to Group B; however, Tm remained comparable (19 ± 2 vs. 20 ± 2 days; P = 0.419). Occurrence of hypovitaminosis-D was lower (23.3%) compared to Indian prevalence rates and was a risk factor for developing active disease (Odds Ratio (OR) = 7.52 [95% Confidence Interval (CI) 2.67–21.16], P < 0.0001). Vitamin D deficiency was significantly (P < 0.001) more common in female gender, active disease, and shorter mean disease duration. Vitamin D levels were inversely correlated to disease activity as assessed by DAS-28 (r = –0.604; P < 0.001). Conclusions: Vitamin-D deficiency is a risk factor for developing active disease in RA. Weekly supplementation of 60,000 IU of 1,25 dihydroxy vitamin D3 in early RA results in greater pain relief. The number needed to treat for this additional pain relief was 2. Identifier: CTRI/2018/01/011532 (www.ctri.nic.in).
Collapse
Affiliation(s)
- Dibyendu Mukherjee
- Department of General Medicine, KPC Medical College and Hospital, Kolkata, West Bengal, India
| | - Sandeep Lahiry
- Department of Pharmacology, RG Kar Medical College, Kolkata, West Bengal, India
| | - Sayanta Thakur
- Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | | |
Collapse
|
9
|
Lahiry S, Choudhury S, Mukherjee A, Chakraborty DS. PubMed indexing: Misconceptions. Indian J Dermatol Venereol Leprol 2018; 84:220-221. [PMID: 29350204 DOI: 10.4103/ijdvl.ijdvl_555_17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Sandeep Lahiry
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | - Shouvik Choudhury
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | - Ayan Mukherjee
- Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
| | | |
Collapse
|